(Finance) – Bristol Myers Squibbone of the world’s leading pharmaceutical companies, has completed the public purchase offer (OPA) for the acquisition of all outstanding common shares of RayzeBiofor a purchase price of $62.50 per share in cash, or approximately $4.1 billion.
As of the expiration date, approximately 53,052,499 ordinary shares of RazyeBio were validly tendered, representing approximately86% of shares issued and outstanding. The parties expect that the transaction will close on February 26, 2024, following the acceptance of all ordinary shares validly tendered.